EMA has resumed clinical data publication for medicines with new active substances that received a CHMP opinion from September 2023 onwards, or were withdrawn before the opinion stage. EMA continues publishing clinical data for COVID-19 medicines. More information is available on EMA's corporate website.

12/09/2024: Clinical data published

The clinical data refer to Zegalogue, a medicine indicated for treatment of severe hypoglycaemia in adults, adolescents and children aged 6 years and over with diabetes mellitus. More information on Zegalogue is available on EMA's corporate website.

12/09/2024: Clinical data published

The clinical data refer to Altuvoct, a medicine indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency), in all age groups. More information on Altuvoct is available on EMA's corporate website.

12/09/2024: Clinical data published

The clinical data refer to Jeraygo, a medicine used to treat resistant hypertension in adults. More information on Jeraygo is available on EMA's corporate website.

05/09/2024: Clinical data published

The clinical data refer to mRESVIA, a medicine indicated for prevention of lower respiratory tract disease and acute respiratory disease caused by respiratory syncytial virus. It is indicated for adults 60 years and older. More information on mRESVIA is available on EMA's corporate website.

02/09/2024: Clinical data published

The clinical data refer to Nezglyal, a medicine for which the CHMP refused the granting of marketing authorisation. This medicine was intended for the treatment of cerebral adrenoleukodystrophy, a genetic condition that damages the membrane covering nerve cells in the brain and spinal cord. More information on Nezglyal is available on EMA's corporate website. 

28/08/2024: Clinical data published

The clinical data refer to Awiqli, a medicine indicated for treatment of diabetes mellitus in adults. More information on Awiqli is available on EMA's corporate website. 

21/08/2024: Clinical data published

The clinical data refer to Cejemly, a medicine indicated for the first line treatment of adults with metastatic non small cell lung cancer (NSCLC), under certain conditions. More information on Cejemly is available on EMA's corporate website.

14/08/2024: Clinical data published

The clinical data refer to a final report from a study evaluating the safety, reactogenicity and immunogenicity of Jcovden and influenza vaccines in healthy adults. More information on Jcovden is available on EMA's corporate website.

14/08/2024: Clinical data published

The clinical data refer to Fruzaqla. The active substance Fruquintinib (HMPL-013) is a small molecule antitumor quinazoline class tyrosine kinase inhibitor, highly selective and potent inhibitor of the vascular endothelial growth factor receptor (VEGFR). The underlying signaling pathway plays a key role in tumor angiogenesis and tumor growth. Thus, targeting of the VEGF signaling pathway is a well-accepted strategy for anticancer therapy. More information on Fruzaqla's is available on EMA's corporate website.

01/08/2024: Clinical data published

The clinical data refer to Obgemsa (vibegron), a medicine indicated for the treatment of adults with overactive bladder syndrome. More information on Obgemsa is available on EMA’s corporate website.

01/08/2024: Further clinical for COVID-19 medicine published

The clinical data refer to a final report from a study evaluating the safety and immunogenicity of COVID-19 vaccine Nuvaxovid in previously vaccinated people. More information on Nuvaxovid is available on EMA’s corporate website.

01/08/2024: Clinical data published

The clinical data refer to Emblaveo (aztreonam/avibactam), a medicine indicated for the treatment of adults with complicated urinary tract infections and hospital-acquired pneumonia. More information on Emblaveo is available on EMA’s corporate website.

25/07/2024: Further clinical data for COVID-19 medicine published

The clinical data refer to a final report from a study evaluating the safety and immunogenicity of COVID-19 vaccine Vaxzevria in previously vaccinated and unvaccinated adults. More information on Vaxzevria is available on EMA’s corporate website.

25/07/2024: Clinical Data published

The clinical data refer to Fabhalta (iptacopan), a medicine used in adults with paroxysmal nocturnal haemoglobinuria (PNH) to treat haemolytic anaemia. More information on Fabhalta is available on EMA’s corporate website.

22/07/2024: Further clinical data for COVID-19 medicine published

The clinical data on the COVID-19 vaccine Jcovden refer to a final report from three studies conducted in people aged 18 or older with no new safety concerns. More information on Jcovden is available on EMA’s corporate website.

28/06/2024: Further clinical data for COVID-19 medicine published

The clinical data on COVID-19 vaccine Spikevax refer to final reports of two studies evaluating the safety and immunogenicity of its mRNA-1273 booster when administered in combination with other vaccines in adults. More information on Spikevax is available on EMA's corporate website.

28/06/2024: Clinical data published

The clinical data refer to Filspari (sparsentan), a medicine for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). More information on Filspari is available on EMA's corporate website.

26/06/2024: Clinical data published

The clinical data refer to Voydeya (danicopan), a medicine indicated as an add-on therapy to ravulizumab or eculizumab for the treatment of residual haemolytic anaemia in adult patients with paroxysmal nocturnal haemoglobinuria (PNH). More information on Voydeya is available on EMA's corporate website.

19/06/2024: Clinical data published

The clinical data refer to Incellipan, a monovalent inactivated influenza vaccine, which uses surface antigens from a potential pandemic H5N1 virus strain candidate. More information on Incellipan is available on EMA’s corporate website.

19/06/2024: Clinical data published

The clinical data refer to Celldemic, a monovalent inactivated influenza vaccine, which uses surface antigens from a potential pandemic H5N1 virus strain candidate. More information on Celldemic is available on EMA’s corporate website.

13/06/2024: Clinical data published

The clinical data refer to Ryzneuta (efbemalenograstim alfa), a medicine indicated for the treatment of neutropenia in adult patients receiving cytotoxic chemotherapy for malignant disease (with some exceptions). More information on Ryzneuta is available on EMA’s corporate website.

13/06/2024: Clinical data published

The clinical data refer to Exblifep (cefepime / enmetazobactam), a medicine indicated for the treatment in adults of infections such as complicated urinary tract infections and hospital-acquired pneumonia. More information on Exblifep is available on EMA’s corporate website.

13/06/2024: Clinical data published

The clinical data refer to Velsipity (etrasimod), a medicine indicated for the treatment of moderately to severely active ulcerative colitis in patients aged 16 years and older. More information on Velsipity is available on EMA’s corporate website.

06/06/2024: Clinical data published

The clinical data refer to Tizveni (tislelizumab), indicated in the treatment of adult patients with locally or metastatic non-small cell lung cancer (NSCLC). More information on Tizveni is available on EMA's corporate website.

06/06/2024: Clinical data published

The clinical data on COVID-19 vaccine Bimervax refer to a final report from a study evaluating the safety and immunogenicity of booster vaccination in adults previously vaccinated against COVID-19. More information on Bimervax is available on EMA's corporate website.

30/05/2024: Further clinical data for COVID-19 medicine published

The clinical data on COVID-19 vaccine Spikevax refer to a final report from a study evaluating the efficacy, safety and immunogenicity of its mRNA-1273 booster in adults. More information on Spikevax is available on EMA's corporate website.

30/05/2024: Clinical data published

The clinical data refer to Zynyz (retifanlimab), an orphan medicine used in adults to treat Merkel cell carcinoma (a type of skin cancer) that cannot be cured by surgery or radiation therapy. More information on Zynyz is available on EMA's corporate website.

30/05/2024: Clinical data published

The clinical data refer to Skyclarys (omaveloxolone), an orphan medicine indicated for the treatment of Friedreichs ataxia in patients aged 16 years and older. More information on Skyclarys is available on EMA's corporate website.

16/05/2024: Clinical data published

The clinical data refer to Casgevy (exagamglogene autotemcel), an orphan medicine used to treat blood disorders known as beta thalassaemia and sickle cell disease in patients aged 12 and older. More information on Casgevy is available on EMA's corporate website.

26/04/2024: Further clinical data for COVID-19 medicine published

The clinical data for COVID-19 vaccine Vaxzevria support a safety and efficacy update on adverse drug reactions frequency. This is based on final analysis from studies including COV001, COV002, COV003 and COV005. More information on Vaxzevria is available on EMA's corporate website.

17/04/2024: Clinical data published

The clinical data refer to Vanflyta (quizartinib), a medicine indicated for adult patients with newly diagnosed acute myeloid leukaemia (AML) FLT3-ITD positive. More information on Vanflyta is available on EMA's corporate website.

15/04/2024: Further clinical data for COVID-19 medicine published

The clinical data refer to several study reports on COVID-19 medicine Xevudy (sotrovimab), assessing its dosage recommendations, administration instructions, efficacy, pharmacokinetic and safety information. More information on Xevudy is available page on EMA's corporate website.

12/04/2024: Clinical data published

The clinical data refer to Rystiggo (rozanolixizumab), a medicine indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. More information on Rystiggo is available on EMA's corporate website.

02/04/2024: Clinical data published

The clinical data refer to Omjjara (momelotinib), a medicine indicated for the treatment of disease-related splenomegaly (enlarged spleen) or other symptoms in adult patients with moderate to severe anaemia who have one of the following rare diseases: primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. More information on Omjjara is available on EMA's corporate website.

27/03/2024: Clinical data published

The clinical data refer to Agamree (vamorolone), an orphan medicine indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged four and older. More information on Agamree is available on EMA's corporate website.

26/03/2024: Clinical data published

The clinical data refer to Loargys (pegzilarginase), an orphan medicine indicated for the treatment of arginase 1 deficiency (ARG1 D) - also known as hyperargininemia - in adults, adolescents and children aged two and older. More information on Loargys is available on EMA's corporate website. 

21/03/2024: Clinical data published

The clinical data refer to Vueway (gadopiclenol), a contrast agent to improve images obtained through magnetic resonance imaging (MRI). It is used for the diagnosis in adults and children aged two and older of pathologies with disruption of the blood brain barrier (BBB) or abnormal vascularity of other organs. More information is available on EMA's corporate website.

15/03/2024: Further clinical data for COVID-19 medicine published

The clinical data support a modified dosage for COVID-19 vaccine Nuvaxovid boosters meant for adolescents, based on interim results from a study evaluating efficacy, safety and immunogenicity. More information is available on the Nuvaxovid page on EMA's corporate website.

14/03/2024: Further clinical data for COVID-19 medicine published 

The clinical data refer to a study report assessing the immunogenicity, safety and tolerability of administering COVID-19 medicine Ronapreve (casirivimab / imdevimab) together with the Moderna mRNA-1273 vaccine in healthy adults. More information is available on the Ronapreve page on EMA's corporate website.

14/03/2024: Clinical data published

The clinical data refer to Elucirem (gadopiclenol), a contrast agent to improve images obtained through magnetic resonance imaging (MRI). It is used for the diagnosis in adults and children aged two and older of pathologies with disruption of the blood brain barrier (BBB) or abnormal vascularity of other organs. More information is available on EMA's corporate website.

11/03/2024: Clinical data published

The clinical data refer to Krazati (Adagrasib) a medicine indicated as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC). More information is available on EMA's corporate website.

07/03/2024: Clinical data published

The clinical data refer to Jivadco (Trastuzumab duocarmazine) a medicine indicated as monotherapy for the treatment of adult patients with HER-2 positive metastatic breast cancer. More information is available on EMA's corporate website.

07/03/2024: Further clinical for COVID-19 medicine published

The clinical data support a modified composition for COVID-19 vaccine Nuvaxovid, introducing a new variant strain (XBB.1.5) with an updated posology regimen and recommendations, and updated safety and efficacy information, based on study results.

07/03/2024: Further clinical data for COVID-19 medicine published

The clinical data refer to several clinical studies supporting updates of efficacy, safety, and pharmacokinetic information for Paxlovid (nirmatrelvir / ritonavir). More information is available on the Paxlovid page on EMA's corporate website.